Invivoscribe launched PrepQuant, an extraction-free sample preparation system designed to standardize pre-analytical workflows for molecular testing. The platform integrates nucleic acid extraction, concentration, and quantification into a single automated instrument and is intended to reduce inconsistency that can undermine measurable residual disease (MRD) and liquid biopsy results. Developed in collaboration with Hitachi High-Tech, PrepQuant is assay agnostic and validated for blood, plasma, and bone marrow specimens. The company positions the technology as a cost and error-reduction layer that supports qPCR, digital PCR, and NGS use cases—an increasingly critical requirement as labs seek traceability and repeatability across high-volume testing.